



**14 February 2017**

## **Share Purchase Plan**

Dear Shareholder

Your directors are pleased to invite you to participate in an opportunity to subscribe for additional ordinary shares in Biotech Capital Limited (BTC) under a share purchase plan (SPP).

The SPP is offered to shareholders who at the record date of 7pm (Sydney time) on 13 February 2017 have a registered address in Australia or New Zealand (Eligible Shareholder).

The 11c issue price represents a 8.33% discount to the last ASX traded price of BTC shares on 10 February 2017 and a 8.33% discount to the volume average market price of shares traded on ASX in the ten days up to the close of trading on 10 February 2017. The SPP issue price is the same price that was offered to placees under the private placement completed on 13 February 2017.

Proceeds from the private placement and the SPP will be used to expand the service offering of the group in providing regulatory, quality and clinical services, opening a Melbourne based Biointelect office, proceeding with key person appointments and to pursue the in-licensing and acquisition of intellectual property.

The SPP will enable Eligible Shareholders, regardless of the number of shares they hold in BTC, to subscribe for their choice of any one of the following parcels of shares:

- 22,727 shares for the total amount of A\$2,500;
- 45,454 shares for the total amount of A\$5,000;
- 68,181 shares for the total amount of A\$7,500;
- 90,909 shares for the total amount of A\$10,000;
- 136,363 shares for the total amount of A\$15,000.

The SPP provides Eligible Shareholders with the opportunity to increase smaller holdings into larger and more financially viable parcels and expand shareholdings without the cost of brokerage or commission.

If an over subscription for shares occurs by the closing date, the directors of BTC will, in their absolute discretion, scale back some or all applications. The SPP will open on Thursday, 16 February 2017 and close at 5pm (Sydney time) on Thursday, 2 March 2017 with shares expected to be allotted on 9 March 2017.

This SPP is optional and the offer is non-renounceable. Accordingly, Eligible Shareholders cannot transfer to other parties their right to subscribe for shares under the SPP. All shares issued under the SPP will rank equally with the existing ordinary shares of BTC and will carry the same rights.

If you wish to participate in the SPP, you can choose either of the following payments methods:

- payment by BPAY<sup>®</sup> – please refer to the Biller code and Reference number on the application form and contact your participating financial institution to make your payment. You are not required to return the application form;



- payment by cheque, money order or bank draft – if paying by this method, complete the application form, attach your cheque, money order or bank draft in Australian dollars, drawn on a bank or financial institution in Australia and made payable to Biotech Capital Limited and return them in the envelope provided.

No cash or card payments will be accepted.

Full details of the SPP are set out in the attached Terms and Conditions. I recommend that you read the Terms and Conditions before making a decision regarding your participation in the SPP. I encourage you to contact your professional adviser if you are uncertain as to what action you should take.

If you have any questions in relation to the SPP, please contact Biotech Capital on +61 3 9092 0470

Yours sincerely

**Richard Treagus**  
**Executive Chairman**



**BIOTECH CAPITAL LIMITED**

**ABN 45 091 979 172**

**SHARE PURCHASE PLAN 2017  
OFFER BOOKLET**

An invitation to shareholders of Biotech Capital Limited to purchase additional fully paid ordinary shares in Biotech Capital Limited under the terms and conditions of this Share Purchase Plan

**Indicative Timetable**

<b>Event</b>	<b>Date</b>	<b>Description</b>
Record date	13 February 2017 7.00pm Sydney time	Eligible shareholders determined
Announcement date	14 February 2017	Share Purchase Plan announced
Dispatch date	16 February 2017	Offer Document dispatched
Opening date	16 February 2017	SPP Opens
Closing date	2 March 2017	SPP Closes
Allotment date	9 March 2017	Shares Issued under SPP
Quotation commences	10 March 2017	Shares issued under SPP expected to commence quotation on ASX

This is an important document and should be read in its entirety.

The Share Purchase Plan provides Eligible Shareholders with the opportunity to purchase additional Biotech Capital Limited shares without brokerage and transaction costs.

The Share Purchase Plan does not take into account the individual investment objectives, financial situation or particular needs of each Eligible Shareholder. Accordingly, before making a decision whether or not to subscribe for Shares in the Share Purchase Plan, you should consult your financial or other professional adviser.

This document is not a prospectus or other disclosure document under the Corporations Act.

**NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO US PERSONS**



## TERMS AND CONDITIONS

---

### 1. **SPP**

- (a) This SPP is an invitation to Eligible Shareholders made by Biotech Capital Limited (**Biotech Capital**) to subscribe for fully paid ordinary shares in Biotech Capital (**New Shares**) at the Issue Price (refer to clause 5) per New Share.
  - (b) The minimum application amount under the SPP is \$2,500.
  - (c) The amount an Eligible Shareholder can apply for will be restricted to a cumulative total of \$15,000.
  - (d) The SPP is conducted under ASIC Class Order CO09/425. The instrument grants relief from the requirement to prepare a prospectus for the offer of New Shares under the SPP.
  - (e) You are not obliged to accept or otherwise participate in the SPP. Participation is optional.
  - (f) The SPP is made to each Eligible Shareholder on the same terms and conditions.
  - (g) The offer under the SPP is non-renounceable, which means that you may not transfer your right to apply for New Shares under the SPP to any other person.
- 

### 2. **Closing Date**

The SPP is scheduled to close at 5:00pm (Sydney time) on 2 March 2017.

Biotech Capital reserves the right to change the closing date of the SPP.

No late applications will be accepted.

---

### 3. **Eligible Shareholders**

- (a) You are eligible to participate in the SPP (**Eligible Shareholder**) if you were a registered holder of fully paid ordinary shares in Biotech Capital (**Shares**) at 7:00pm (Sydney time (AEST)) on 13 February 2017 (**Record Date**) whose address in the security register of Biotech Capital is in Australia or New Zealand, unless:
  - (i) you hold Shares on behalf of another person who resides outside Australia or New Zealand and do not hold Shares in any other capacity;
  - (ii) you are resident in the United States or acting for the account or benefit of a person resident in the United States; or
  - (iii) you are ineligible to participate in the SPP because of the aggregate limit explained in clause 7.
- (b) This SPP does not constitute an offer in any jurisdiction in which or to any person to whom it would be unlawful to make such an offer. Biotech Capital reserves the right to reject any acceptance which it believes comes from a person who is not an Eligible Shareholder.
- (c) (**Single Holders**) If you are the only registered holder of Shares, but you receive more than one offer under the SPP (for example, due to multiple registered holdings), you may only apply for New Shares up to a maximum aggregate value of \$15,000.
- (d) (**Joint Holders**) If you are recorded with one or more other persons as the joint holder of Shares, that joint holding is considered to be a single registered holding for the purposes of the SPP. Subject to the conditions of eligibility as set out in this clause 3, the joint holders are entitled to participate in the SPP in respect of that single holding only. The certification under clause 9 by one of the joint holders will be effective in respect of the other joint holder(s). If the same joint holders receive more

than one offer under the SPP due to multiple registered holdings, the joint holders may only apply for New Shares up to a maximum aggregate value of \$15,000.

- (e) **(Custodians)** If you are a custodian within the definition of “Custodian” in ASIC Class Order CO09/425 and you are a registered holder of Shares on behalf of another person (**Beneficiary**) and you apply to acquire New Shares on behalf of the Beneficiary, you must certify in writing Biotech Capital a number of matters relating to such beneficiaries (**Custodian Certificate**).
- (f) If you are a Custodian, please contact Biotech Capital Limited, on +61 3 9092 0470 for the Custodian Certificate required under these SPP terms and conditions.
- (g) If you are a Custodian and you hold shares or interests jointly on behalf of two or more persons, the \$15,000 limit applies jointly in relation to those persons as if you hold the shares or interests on behalf of a single person.
- (h) **(Trustees and Nominees)** If you hold Shares as a trustee or nominee for another person, but are not a Custodian as defined above, you cannot participate a Beneficiary in the manner described above. In this case, the rules for multiple single holders (as above) will apply.
- (i) Nominees and other registered holders of Shares that are acting on behalf of a person in the United States or any other country outside Australia and New Zealand, must not:
  - (i) send this document or any other document relating to the SPP to any person in the United States or any other country outside Australia and New Zealand; or
  - (ii) purport to exercise rights under this offer on behalf of a person in the United States or any other country outside Australia and New Zealand.

#### 4. **Making an application for New Shares**

- (a) Applications under the SPP may only be made for the following amounts:

Total investment	\$2,500	\$5,000	\$7,500	\$10,000	\$15,000
New Shares issued	22,727	45,454	68,181	90,909	136,363

- (b) Eligible Shareholders are not permitted to acquire more than \$15,000 worth of New Shares in aggregate, even if you receive more than one SPP Application Form (**Application Form**) or hold Shares in more than one capacity, e.g. if you are both a sole and joint holder of Shares (**Aggregate SPP Participation**).

#### 5. **Issue Price of New Shares under the SPP**

- (a) The price per New Share on offer under the SPP (**Issue Price**) will be \$0.11 (11 cents).
- (b) The current Share price can be obtained from the ASX website ([www.asx.com.au](http://www.asx.com.au)) (ASX code: BTC) and is listed in the financial and business section of major daily newspapers circulated in Australia.
- (c) The Issue Price represents a discount of 8.33% to the volume weighted average price of the past 10 trading days prior to announcement, and a 8.33% discount to the closing price on the record date of 13 February 2017.
- (d) You agree to pay the Issue Price for each New Share calculated under clauses 5(a) and 7(b).
- (e) You acknowledge that the market price of Shares may rise or fall between the date of this SPP, the date of calculation of the Issue Price and the date that New Shares are

allotted to you under the SPP (**Issue Date**) and that the effect of this is that the Issue Price you pay for the New Shares may exceed the market price of New Shares on the Issue Date.

## 6. **Scale back**

- (a) Biotech Capital reserves the right to allot fewer New Shares than an Eligible Shareholder applies for under the SPP, or no New Shares. Any determination by the Directors in respect of any scale back will be final.
- (b) If a scale back occurs, Biotech Capital will refund the balance of application monies, without interest, following allotment by way of cheque to the applicant's registered address.

## 7. **Applying for Shares under the SPP**

- (a) If you are an Eligible Shareholder and wish to participate in the SPP, you must follow the instructions on the Application Form and:
  - (i) make payment by BPAY<sup>®</sup> equivalent to the value of the parcel of New Shares you wish to apply for, using the information provided on the Application Form; or
  - (ii) complete the Application Form and provide a cheque or money order made payable to "Biotech Capital Limited", delivered to the Share Registry,
 so that payment is received by the Share Registry by 5:00pm (Sydney time) on the Closing Date. Payments must be denominated in Australian dollars.

### SHARE REGISTRY

Postal delivery	Hand delivery
Biotech Capital Limited C/- Link Market Services Limited GPO Box 3560 Sydney NSW 2001	Biotech Capital Limited C/- Link Market Services Limited 1A Homebush Bay Drive Rhodes NSW 2138 <b><i>(Please do not use this address for mailing purposes)</i></b>

- (b) If you apply for New Shares, you will apply for a specified value, rather than a specified number of New Shares. Subject to clause 7(c), Biotech Capital will divide the parcel value that you select by the Issue Price in order to determine the number of New Shares for which you have applied (rounded down to the nearest whole number of New Shares). Any balance of monies sent by you that is remaining as a result of rounding will be refunded to you except where the amount is less than \$2.00 (or an amount advised by Biotech Capital).
- (c) Eligible Shareholders who receive more than one offer under the SPP (for example because they hold Shares in more than one capacity) may apply on different Application Forms for New Shares, but may not apply for New Shares with an aggregate value of more than \$15,000.
- (d) Biotech Capital may accept or reject your application for New Shares, either in whole or in part, at its absolute discretion. For example, Biotech Capital may reject your application in circumstances such as the following (among others):
  - (i) it appears that you are applying to purchase a number of New Shares that will mean that your Aggregate SPP Participation will exceed \$15,000;

- (ii) your Application Form is incorrectly completed, incomplete or otherwise determined by Biotech Capital to be invalid;
- (iii) your cheque is dishonoured or the cheque or money order that you enclose with your Application Form is not made out for the amount corresponding to the value of the parcel of New Shares for which you have applied;
- (iv) your Application Form is received after the Closing Date; or
- (v) Biotech Capital believes you are not an Eligible Shareholder (subject to compliance with any applicable ASIC or ASX requirements).

Late or otherwise incomplete or invalid payments will be refunded to you.

- (e) You should be aware that your own financial institution may implement earlier cut off times with regards to electronic payment, and you should therefore take this into consideration when making payment.
- (f) The lodgement of the Application Form with the application monies, or the remittance of funds via BPAY<sup>®</sup> will constitute the Eligible Shareholder's offer to subscribe for shares on the terms and conditions of this SPP. Once an application has been made, it cannot be revoked. No notice of acceptance of the application will be provided.

---

## **8. Shortfall**

The offer under the SPP is not underwritten. The offer under the SPP has no minimum total raise requirements and as such no shortfall will occur.

---

## **9. Certification by Eligible Shareholders and Custodians**

- (a) If you submit a BPAY<sup>®</sup> payment or complete and return an Application Form together with a cheque or money order:
  - (i) you acknowledge that you are an Eligible Shareholder;
  - (ii) you irrevocably and unconditionally agree to the Terms and Conditions and the terms of the Application Form and agree not to do any act or thing that would be contrary to the spirit, intention or purpose of the SPP or these Terms and Conditions;
  - (iii) you acknowledge that your application is irrevocable, unconditional and cannot be withdrawn once returned;
  - (iv) you certify that the aggregate of the application price for the following does not exceed \$15,000:
    1. New Shares under the SPP the subject of your application;
    2. any other New Shares or interests under the SPP or any Shares or interests in the class of shares issued that you acquired under any similar arrangement in the 12 months before the date of your application;
    3. any other New Shares or interests in the class of shares issued which you have instructed a Custodian to acquire on your behalf under the SPP; and
    4. any other Shares or interests in the class of shares issued to a Custodian under an arrangement similar to the SPP in the 12 months before the date of your application as a result of an instruction given by you to the



5. Custodian or another Custodian and which resulted in you holding beneficial interests in the shares or interests in the class, even though you may have received more than one offer under the SPP or received offers in more than one capacity under the SPP;
- (b) If you are a Custodian, you make additional representations that you either:
    - (i) hold an Australian financial services licence that:
      1. covers the provision of a custodial or depository service (as defined by section 766E of the Corporations Act; or
      2. includes a condition requiring you to comply with the requirements of ASIC Class Order CO13/763; or
    - (ii) are exempt from the requirement to hold an Australian financial services licence for the provision of a custodial or depository service under:
      1. paragraph 7.6.01(1)(k) or paragraph 7.6.01(1)(na) of the *Corporations Regulations 2001* (Cth);
      2. ASIC Class Order CO05/1270 to the extent that it relates to ASIC Class Order CO03/184;
      3. ASIC Class Orders CO03/1099, CO03/1100, CO03/1101, CO03/1102, CO04/829 or CO04/1313;
      4. an individual instrument of relief granted by ASIC in terms similar to one of the Class Orders referred to in paragraph (iii) above;
      5. paragraph 911A(2)(h) of the Corporations Act; or
    - (iii) are otherwise a Custodian as defined in Class Order CO09/425 and that you have provided a Custodian Certificate to Biotech Capital;
  - (c) you authorise Biotech Capital to correct minor errors in your Application Form and to complete the Application Form by inserting any missing minor information;
  - (d) you accept the risk associated with any refund that may be sent to your address or to your nominated bank account as shown on Biotech Capital's share register;
  - (e) you acknowledge that no interest will be paid on any application monies held pending the allotment of the SPP Shares or subsequently refunded to you for any reason;
  - (f) you acknowledge that Biotech Capital and the Share Registry have not provided any investment advice or financial product advice, and that none of them has any obligation to provide this advice in relation to your consideration as to whether or not to participate in the SPP;
  - (g) you acknowledge that Biotech Capital (and each of its officers and agents) is not liable for any consequences of the exercise or non-exercise of its discretions referred to in the SPP;
  - (h) you acknowledge that the SPP Shares have not, and will not be, registered under the US Securities Act of 1933 or the securities law of any other jurisdiction outside Australia or New Zealand and, accordingly, the New Shares may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and any other applicable securities laws;
  - (i) you agree not to send the SPP or any other material relating to the SPP to any person in the United States or any other country outside Australia and New Zealand;
  - (j) you acknowledge that Biotech Capital may at any time irrevocably determine that your application is valid, in accordance with the terms and conditions of the SPP, even if the Application Form is incomplete, contains errors or is otherwise defective;



- (k) you are responsible for any dishonour fees or other costs that Biotech Capital may incur in presenting a cheque or money order for payment that is dishonoured; and
- (l) if two or more persons are recorded in Biotech Capital's register of members as jointly holding Shares or interest in Biotech Capital, they are taken to be a single registered holder and a certification given by any of them is taken to be a certification given by all of them.

## **10. Issue of New Shares**

Biotech Capital will not be obliged to allot New Shares and the applicant will not be entitled to receive or be issued New Shares until the Board resolves to allot the New Shares.

New Shares under the SPP will be allotted and issued on or about 9 March 2017. After all New Shares have been allotted, Biotech Capital will promptly make application to ASX Limited for the New Shares to be admitted to quotation.

Holding statements will be despatched shortly after the Allotment Date.

## **11. Indicative Timetable**

<b>Event</b>	<b>Date</b>	<b>Description</b>
Record date	13 February 2017 7.00pm Sydney time	Eligible shareholders determined
Announcement date	14 February 2017	Share Purchase Plan announced
Dispatch date	16 February 2017	Offer Document dispatched
Opening date	16 February 2017	SPP Opens
Closing date	2 March 2017	SPP Closes
Allotment date	9 March 2017	Shares Issued under SPP
Quotation commences	10 March 2017	Shares issued under SPP expected to commence quotation on ASX

These dates are indicative only. Biotech Capital may vary the dates and times of this offer or withdraw it without notice. Accordingly, Eligible Shareholders are encouraged to submit their Application Forms as early as possible.

## **12. Additional Terms of this SPP**

The requirements of the Australian Securities and Investments Commission's Class Order CO 09/425 are incorporated into this SPP.

Under that Class Order, the yearly limit that can be raised from a participant in a share purchase plan is \$15,000. Accordingly, no Eligible Shareholder (including through joint holdings, multiple share accounts or any holding in which the Eligible Shareholder may have a beneficial interest) will be issued with shares under this or any other share purchase plan with an application value totalling more than \$15,000 in any consecutive 12-month period.

All New Shares issued under the SPP will rank equally with existing Shares.

The SPP is administered by the Board of Biotech Capital which may determine in any manner it thinks fit, any difficulties, anomalies or disputes which may arise in connection

with or by reason of the operation of the SPP whether generally or in relation to any participant, or application, or Shares and the determination of the Board will be conclusive and binding on all participants and other persons to whom the determination relates.

The Board reserves the right to withdraw this SPP and any offer under it at any time prior to the allotment of Shares and to waive strict compliance with any provision of these terms and conditions, to amend or vary these terms and conditions and to suspend or terminate the SPP at any time. If the SPP is withdrawn, all application monies will be refunded without interest.

---

**13. Costs of Participation**

There are no brokerage, commissions or other participation costs payable by you in respect of any acquisition of New Shares under this SPP.

---

**14. Risks**

Potential investors should consider the risks that could affect Biotech Capital before deciding to invest. Risk factors include but are not limited to:

- (a) the speculative nature of the investment;
- (b) risks related to general market conditions including exchange rate risk, interest rates, market sentiment and circumstances and conditions which are not within Biotech Capital's control;
- (c) biotechnology and pharmaceutical risks;
- (d) environmental regulation risks;
- (e) regulatory risks in general, including the risk of legislative and regulatory changes, native title and Aboriginal cultural heritage risks;
- (f) commercial risks including transport, power and carbon sale and pricing risk;
- (g) reliance on key management personnel and employees; and
- (h) financing risks.

Potential investors should carefully consider the risks in light of their personal circumstances (including financial and taxation issues) and seek professional advice from their stockbroker, accountant, lawyer or other professional adviser.

---

**15. New Zealand**

- (a) The New Shares are not being offered or sold to the public within New Zealand other than to existing shareholders of Biotech Capital with registered addresses in New Zealand to whom the offer of New Shares is being made in reliance on the Securities Act (Overseas Companies) Exemption Notice 2002 (New Zealand).
- (b) This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Securities Act 1978 (New Zealand). This document is not an investment statement or prospectus under New Zealand law and is not required to, and may not, contain all the information that an investment statement or prospectus under New Zealand law is required to contain.

---

**16. United States**

- (a) This document may not be released or distributed in the United States. The Shares have not been and will not be registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States.
- (b) The Shares may not be taken up by persons in the United States or by persons who are acting for the account or benefit of a person in the United States. The Shares may not be offered, sold or resold in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and the applicable securities laws of any state or other jurisdiction in the United States.

---

**17. Queries**

If you have any queries concerning the SPP, please call Biotech Capital Limited on 03 9092 0470.

**Further Information**

Please refer to the latest releases on Biotech Capital's website [www.biotechcapital.com.au](http://www.biotechcapital.com.au)

In addition, information on Biotech Capital's recent activities is available from the Company's ASX announcements which can be accessed on the ASX website at [www.asx.com.au](http://www.asx.com.au) (ASX Code: BTC).

**SRN/HIN:**  
**Entitlement Number:**  
**Record Date:** 13 February 2017  
**Offer Opens:** 13 February 2017  
**Issue Price per Share:** A\$0.11

<b>Offer Closes</b> 5.00pm (AEDT):	<b>2 March 2017</b>
---------------------------------------	---------------------

**SHARE PURCHASE PLAN ("SPP") APPLICATION FORM**

**How do I apply for Shares under this offer?**

- Carefully read the SPP Terms and Conditions accompanying this form.
- Decide on the amount you wish to apply for.
- Pay for the Shares in accordance with the instructions outlined in the Terms and Conditions Booklet and further important instructions on the reverse of this form.
  - Option 1: Paying by BPAY®.
  - Option 2: Paying by Cheque, Bank Draft or Money Order.
- Payments must be in Australian dollars.

**PAYMENT OPTIONS**

**Option 1: Paying by BPAY®**

If paying by BPAY®, you do **NOT** need to complete or return the Acceptance Slip attached to this Application Form below. Payment must be received by the Payment Processor by BPAY® by 5.00pm (AEDT) on 2 March 2017. By paying by BPAY®, you will be deemed to have completed an Application Form for the number of Shares that is the subject of your Application Payment.

If you make a payment by BPAY® and Biotech Capital Limited receives a payment which is not equal to either A\$2,500, A\$5,000, A\$7,500, A\$10,000 or A\$15,000, Biotech Capital Limited may round down the number of Shares that you are applying for to the next lowest parcel at their discretion. Your payment must be for a minimum of A\$2,500.

<b>BPAY</b>	<b>Billers Code:</b> [XXXXXX]
	<b>Ref:</b>

**Telephone & Internet Banking –**  
 Contact your bank or financial institution to make this payment from your cheque, savings, debit or transaction account. For more info: www.bpay.com.au  
 © Registered to BPAY Pty Ltd ABN 69 079 137 518

**Option 2: Paying by Cheque, Bank Draft or Money Order**

If paying by cheque, bank draft or money order, complete and return the Acceptance Slip attached to this Application Form with your Application Payment.

- Tick the box beside the amount you wish to apply for, either A\$2,500, A\$5,000, A\$7,500, A\$10,000 or A\$15,000.
- Enter your cheque, bank draft or money order details. The amount of your Application Payment should be equal to the amount applied for in section A of the Acceptance Slip. Cheques, bank drafts or money orders must be drawn on an Australian branch of a financial institution in Australian currency, made payable to "Biotech Capital Limited" and crossed "Not Negotiable". Please ensure sufficient cleared funds are held in your account, as your cheque will be banked as soon as it is received. If you provide a cheque, bank draft or money order for an amount that is not equal to either A\$2,500, A\$5,000, A\$7,500, A\$10,000 or A\$15,000, Biotech Capital Limited may round down the number of Shares that you are applying for to the next lowest parcel at their discretion. Your payment must be for a minimum of A\$2,500.
- Enter your contact telephone number at which we may contact you regarding your application for Shares, if necessary.

**THIS IS A PERSONALISED FORM FOR THE SOLE USE OF THE SHAREHOLDER AND HOLDING RECORDED ABOVE.**



**A** I/we wish to purchase a parcel of Shares to the dollar amount of (tick one box only):

<input type="checkbox"/> 22,727 Shares A\$2,500 OR	<input type="checkbox"/> 45,454 Shares A\$5,000 OR	<input type="checkbox"/> 68,181 Shares A\$7,500 OR	<input type="checkbox"/> 90,909 Shares A\$10,000.00 OR	<input type="checkbox"/> 136,363 Shares A\$15,000
---	---	---	---	--

**B** Make your cheque, bank draft or money order payable to "Biotech Capital Limited" and crossed "Not Negotiable"

Drawer	Cheque Number	BSB Number	Account Number	Amount of Cheque
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	A\$ <input type="text"/> .00

**C** Telephone Number – Business Hours      Telephone Number – After Hours      Contact Name

<input type="text"/>	<input type="text"/>	<input type="text"/>
----------------------	----------------------	----------------------

## IMPORTANT INFORMATION

1. This is an important document which requires your immediate attention. If you are in any doubt as to how to deal with this Application Form, please consult a professional adviser.
2. If you do not wish to purchase additional Shares under this SPP, there is no need to take action.
3. Please ensure you have read and understood the SPP Terms and Conditions and this Important Information, before you make the Application Payment by BPAY® or you submit your Acceptance Slip with your Application Payment.
4. This SPP is non-renounceable. Applications can only be accepted in the name printed on the Application Form.
5. If you are a custodian, trustee or nominee within the definition of "custodian" in ASIC Class Order [CO 09/425] you must complete and submit an additional Schedule that contains additional certifications and details that must be provided ("the Schedule") before your Application will be received. The Schedule can be obtained by contacting the Biotech Capital Limited SPP Offer Information Line. Applications received by custodians that are not accompanied by the Schedule will be rejected.
6. For applicants that are not required to complete the Schedule, by submitting the Acceptance Slip (with a cheque, bank draft or money order) or making payment by BPAY®, you certify that the aggregate of the Application Payment paid by you for:
  - the parcel of New Shares indicated on this Application Form or BPAY® payment; and
  - any other Shares applied for by you, or which you have instructed a Custodian to acquire on your behalf under the SPP or any other similar arrangement in the 12 months prior to the date of submission of the Acceptance Slip or payment by BPAY® does not exceed A\$15,000.
7. Biotech Capital Limited reserves the right to make amendments to this Application Form where appropriate.
8. Applicants are not assured of receiving the Shares for which they have applied as Biotech Capital Limited may make back applications in its discretion.

SAMPLE

### How to Lodge your Acceptance Slip and Application Payment

A reply paid envelope is enclosed for you to return your Acceptance Slip and Application Payment. No postage stamp is required if it is posted in Australia.

Acceptance Slip and the payment for New Shares must be received by the Registry no later than the closing date shown overleaf. If paying by BPAY® you do not need to complete or return the Application Form. You should check the processing cut off-time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Registry by the close of the offer.

#### Mailing Address

Biotech Capital Limited  
C/- Link Market Services Limited  
GPO Box 3560  
Sydney NSW 2001

or

#### Hand Delivery

Biotech Capital Limited  
C/- Link Market Services Limited  
1A Homebush Bay Drive  
Rhodes NSW 2138 **(Please do not use this address for mailing purposes)**

Make sure you send your Acceptance Slip and Application Payment allowing enough time for mail delivery, so Link Market Services Limited receives them no later than 5.00pm (AEDT) on 2 March 2017. Please ensure sufficient cleared funds are held in your account, as your cheque will be banked as soon as it is received. Biotech Capital Limited reserves the right not to process any Acceptance Slips and Application Payments received after the Closing Date.

**If you require information on how to complete this Acceptance Slip please contact Biotech Capital Limited on + 61 3 9092 0470.**